Greenland will vote in a general election on Tuesday seen by some locals as a historic chance to free themselves from Danish ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Swiss wealth-management bank J Safra Sarasin has agreed to buy 70pc of Denmark’s Saxo Bank, in one of the biggest private ...

Adding European shares for diversification could be the answer. The post Worried about US shares? Adding European shares ...

One of the losers of today's trading session was Novo Nordisk A/S. Shares of the Pharmaceutical company plunged -9.8%, and some investors may be wondering if its price of $78.63 would make a good ...

In its Monday update, the FDA clarified that state-licensed compounding pharmacies and outsourcing facilities — which make ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...

Genmab A/S posted the largest decline among large stocks during the session, falling 8.3%, followed by Novo Nordisk A/S shares, which declined 8.1%. Shares of Torm PLC A declined 7.1%.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Leading Russian drugmakers PSK Pharma and Promomed, which produce the analogues of Ozempic - a drug for the treatment of ...

Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...